Novo Nordisk Seeks Injunction Against Eli Lilly's GLP-1 Advertising Amid Stock Buy Rating

Novo Nordisk has filed for a temporary restraining order in the United States to halt Eli Lilly’s advertising of its GLP‑1 weight‑loss medicines. The company alleges that Lilly uses outdated or misinterpreted study data in its campaigns, suggesting greater average weight loss than supported by evidence, and asks that the ads be stopped while the litigation proceeds.

Separately, analysts have initiated coverage of Novo Nordisk with a BUY recommendation and a $68 price target. Their thesis highlights the expanding obesity market, especially the launch of oral Wegovy, strong prescription growth, and a pipeline that includes high‑dose Wegovy, CagriSema and Zenagamtide. Risks noted include competition, pricing pressure and the upcoming 2032 patent cliff for semaglutide.